Loading...
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
BACKGROUND: The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic leukemia (B-ALL). The BCR-ABL tyrosine kinase inh...
Na minha lista:
| Udgivet i: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7302132/ https://ncbi.nlm.nih.gov/pubmed/32552902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00912-3 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|